Clinical Trials Logo
  1. Home
  2. Metastatic Tumor
  3. NCT05717166

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. — SABR-SYNC  

Metastatic Tumor Clinical Trial

Official title:
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

Clinical Trial Summary

This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease. Patients will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis3: histology (Group 1: hormone-sensitive prostate cancer, breast, or renal; Group 2: all others), and number of metastases (Group 1: 1-3; Group 2: 4-10).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05717166
Study type Interventional
Source Lawson Health Research Institute
Contact David Palma, MD, PhD
Phone 519-685-8650
Email David.Palma@lhsc.on.ca
Status Recruiting
Phase Phase 3
Start date October 6, 2023
Completion date April 2029
View Details
See also
  Status Clinical Trial Phase
Completed NCT01648764 - A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread Phase 1
Recruiting NCT05415475 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors Phase 1
Completed NCT03238027 - A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors Phase 1
Terminated NCT05099549 - Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers Phase 1/Phase 2
Recruiting NCT05518253 - A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors Phase 1
Recruiting NCT05396300 - A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors Phase 1
Recruiting NCT05678010 - A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer Phase 1
Recruiting NCT05468190 - A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T Phase 1
Completed NCT02977156 - Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. Phase 1
Recruiting NCT05731271 - A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors Phase 1/Phase 2
Recruiting NCT06264921 - A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors Phase 1
Not yet recruiting NCT05665348 - Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy Phase 2/Phase 3
Recruiting NCT05420545 - A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors Phase 1
Recruiting NCT05420519 - Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer Phase 1
Recruiting NCT06165419 - Definitive Radiation for High-Risk Spine Metastases Phase 2
Not yet recruiting NCT06383507 - A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors Phase 1